


AMENDMENTS TO THE CLAIMS:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compound corresponding to formula I:








I,


wherein

R¹ and **R²** together form the following, each of which is monosubstituted or polysubstituted or unsubstituted:

- (CH₂)_n-, where n = 3-10
- CH=CH-CH₂-, -CH₂-CH=CH-,
- CH=CH-CH₂-CH₂-, -CH₂-CH₂-CH=CH-,
- CH₂-CH=CH-CH₂-,
- CH₂-CH=CH-CH₂-CH₂-, -CH₂-CH₂-CH=CH-CH₂-,
- CH₂-CH₂-CH=CH-CH₂-CH₂-,
- O-CH₂-CH₂-, -CH₂-CH₂-O-,
- O-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-O-,
- CH₂-O-CH₂-,
- CH₂-CH₂-O-CH₂-, -CH₂-O-CH₂-CH₂-,



or



X= O, S

R³ represents

H; C₁-C₁₈-alkyl, C₂-C₁₈-alkenyl or C₂-C₁₈-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by N, S or O; alkylaryl or alkylheteroaryl, each of which is monosubstituted or

polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

R⁴ represents

R^{4a} or **ZR^{4a}**, where **Z** = C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and **R^{4a}** represents

H; C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl or C₂-C₁₂-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

C(O)R⁹, **C(O)OR⁹**, **C(S)R⁹**, **C(S)OR⁹** or **S(O₂)R⁹**, where **R⁹** represents

H; C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted, especially phenethyl, 1-adamantyl, 2-adamantyl, 1-naphthyl or 2-naphthyl, 2-, 3- or 4-pyridyl or thiazolyl;

SR¹⁰, where **R¹⁰** represents

aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

$C(O)NR^{11}R^{12}$, $C(O)NR^{11}NR^{12}R^{13}$, $C(NR^{11})NR^{12}R^{13}$, $C(S)NR^{11}R^{12}$ or $C(S)NR^{11}NR^{12}R^{13}$, where R^{11} , R^{12} and R^{13} independently represent H; C_1 - C_{18} -alkyl, C_2 - C_{18} -alkenyl or C_2 - C_{18} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C_3 - C_8 -cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

R^5 , R^6 , R^7 and R^8 independently represent

H; F; Cl; Br; I; CN; NO_2 ; and C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl or C_2 - C_{10} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted;

OR^{14} , $OC(O)R^{14}$, $OC(S)R^{14}$, $C(O)R^{14}$, $C(O)OR^{14}$, $C(S)R^{14}$, $C(S)OR^{14}$, SR^{14} , $S(O)R^{14}$ or $S(O_2)R^{14}$, where R^{14} represents

H; C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl or C_2 - C_{10} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C_3 - C_8 -cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

$NR^{15}R^{16}$, $NR^{15}C(O)R^{16}$, $C(NR^{15})NR^{16}R^{17}$, $NR^{15}C(S)R^{16}$, $C(S)NR^{15}R^{16}$, $C(S)NR^{15}NR^{16}R^{17}$ or $S(O_2)NR^{15}R^{16}$, where R^{15} , R^{16} and R^{17} independently represent

H; O; C₁-C₁₈-alkyl, C₂-C₁₈-alkenyl or C₂-C₁₈-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

or

R¹⁵ and R¹⁶ or R¹⁶ and R¹⁷ together form a C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; and

R⁵ and R⁶, R⁶ and R⁷ or R⁷ and R⁸ together form


=CR¹⁸-CH=CH-CH= or =CH-CR¹⁸=CH-CH=, where R¹⁸ represents

H; F; Cl; Br; I; OH; and C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted,

in the form of a salt thereof with a base,

provided that


if R¹ and R² together form -CH=CH-CH₂- or



and R³ is (-)-p-menthan-3-ol, R⁷ ≠ Cl and R⁵, R⁶ and R⁸ ≠ H simultaneously,


if R¹ and R² together form -CH=CH-CH₂- and R³ is CH₃, R⁷ ≠ H, Cl or OCH₃ and R⁵, R⁶ and R⁸ ≠ H simultaneously,

if R¹ and R² together form -CH=CH-CH₂- and R³ is H, R⁷ ≠ OCH₃ or C(O)NH₂ and R⁵, R⁶ and R⁸ ≠ H, R⁵ and R⁷ ≠ CH₃ and R⁶ and R⁸ ≠ H, or R⁵ ≠ OCH₃ and R⁶, R⁷ and R⁸ ≠ H simultaneously, or if R¹ and R² together form



or -O-CH₂-CH₂- and R³ is C₂H₅, R⁷ ≠ H, Cl, CH₃, OCH₃ or NO₂ and R⁵, R⁶ and R⁸ ≠ H, or R⁵ ≠ NO₂ and R⁶, R⁷ and R⁸ ≠ H simultaneously.

2. (Original) The compound of claim 1, wherein if R¹ and R² together form -CH=CH-CH₂- or



and R³ is menthol or borneol, R⁷ ≠ Cl and R⁵, R⁶ and R⁸ ≠ H simultaneously.

3. (Original) The compound of claim 1, wherein said compound is present in the form of a pure enantiomer.
4. (Original) The compound of claim 1, wherein said compound is present in the form of a pure diastereoisomer.
5. (Original) The compound of claim 1, wherein said compound is present in the form of a mixture of stereoisomers.
6. (Original) The compound of claim 1, wherein said compound is present in the form of a racemic mixture.

7. (Original) The compound of claim 1, wherein said compound is present in the form of an NH_4^+ , monopotassium, dipotassium, magnesium or calcium salt.

8. (Original) The compound of claim 1, wherein said compound is present in the form of an NH_4^+ salt.

9. (Original) The compound of claim 1, wherein R^4 represents
H; C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl or C_2 - C_{10} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and C_3 - C_8 -cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted; and $\text{C}(\text{O})\text{R}^9$, where R^9 represents

H; C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl or C_2 - C_{10} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C_3 - C_8 -cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted,

10. (Original) The compound of claim 1, wherein R^4 represents
 $\text{C}(\text{O})\text{R}^9$, where R^9 represents phenethyl, 1-adamantyl, 2-adamantyl, 1-naphthyl or 2-naphthyl, 2-, 3- or 4-pyridyl or thiazolyl.


11. (Original) The compound of claim 1, wherein R^4 represents
H, CH_3 or C_2H_5 .

12. (Original) The compound of claim 1, wherein R^3 represents
H; C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl or C_2 - C_{10} -alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C_3 - C_8 -cycloalkyl which is saturated or unsaturated and

monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by N or O; alkylaryl which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted.

13. (Original) The compound of claim 1, wherein R^3 represents H; C_1 - C_4 -alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and phenyl, benzyl or phenethyl which is monosubstituted or polysubstituted or unsubstituted.
14. (Original) The compound of claim 1, wherein R^3 represents H, CH_3 or C_2H_5 .

15. (Original) The compound of claim 1, wherein R^1 and R^2 together form $-O-CH_2-CH_2-$, $(-CH_2-)_n$ where $n = 3-6$, $-CH=CH-CH_2-$, $-CH=CH-CH_2-CH_2-$,



16. (Original) The compound of claim 1, wherein R^1 and R^2 together form $(-CH_2-)_n$ where $n =$ preferably 3 or 6, $-CH=CH-CH_2-$ or $-CH=CH-CH_2-CH_2-$.
17. (Original) The compound of claim 1, wherein R^5 , R^6 , R^7 and R^8 independently represent

H; F; Cl; Br; I; CN; NO₂; and C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted;

OR¹⁴, C(O)R¹⁴, C(O)OR¹⁴ or SR¹⁴; and

NR¹⁵R¹⁶ or NR¹⁵C(O)R¹⁶, R¹⁵ and R¹⁶ independently represent

H; O; C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted.

18. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; NO₂; and C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted;

OR¹⁴, C(O)R¹⁴, C(O)OR¹⁴ or SR¹⁴, where R¹⁴ represents

H; C₁-C₄-alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and aryl which is monosubstituted or polysubstituted or unsubstituted.

19. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; and C₁-C₄-alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted;

OR¹⁴ or SR¹⁴, where R¹⁴ represents

C₁-C₄-alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and aryl which is monosubstituted or polysubstituted or unsubstituted.

20. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; CH₃; CF₃; t-butyl; i-butyl; -OCH₃; -OCF₃; -SCH₃ or -O-phenyl.

21. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; NO₂; CF₃; and C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which is branched or unbranched and unsubstituted; OR¹⁴, C(O)R¹⁴, C(O)OR¹⁴ or SR¹⁴, where R¹⁴ represents

H; C₁-C₄-alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and aryl which is monosubstituted or polysubstituted or unsubstituted.

22. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; CF₃; and C₁-C₄-alkyl which is branched or unbranched and unsubstituted;

OR¹⁴ or SR¹⁴, where R¹⁴ represents

C₁-C₄-alkyl which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and aryl which is monosubstituted or polysubstituted or unsubstituted.

23. (Original) The compound of claim 1, wherein R⁵, R⁶, R⁷ and R⁸ independently represent

H; F; Cl; Br; I; CN; CH₃; CF₃; t-butyl; i-butyl; -OCH₃; -OCF₃; -SCH₃ or -O-phenyl.

24. (Original) The compound of claim 1, wherein

R⁵, R⁶ and R⁸ are H and R⁷ is Cl, or

R⁵ and R⁷ are H and R⁶ and R⁸ are Cl.

25. (Original) The compound of claim 1, wherein said compound is selected from the group consisting of the salts of:

7,9-dichloro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid,
8-chloro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid,
6,8,9-trichloro-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-4-carboxylic acid,
1,3-dichloro-5,6,6a,7,8,12b-hexahydrobenzo[k]phenanthridine-6-carboxylic acid,
1,3-dichloro-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-6-carboxylic acid
and


7,9-dichloro-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[c]quinoline-4-carboxylic acid.

26. (Original) The compound of claim 1, wherein said compound is selected from the group consisting of the salts of:

sodium 7,9-dichloro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylate or

sodium 7,9-dichloro-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[c]quinoline-4-carboxylate.


27. (Previously Presented) A process for preparing a substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compound corresponding to formula I of claim 1, wherein $R^4 = H$,



I,

comprising the steps of:

reacting an aniline corresponding to formula II, a glyoxalic acid ester or a glyoxalic acid corresponding to formula III and an olefin of formula IV, with trifluoroacetic acid.



28. (Original) The process of claim 27, wherein said step of reacting is carried out at a temperature between 0°C and 100°C.

29. (Original) The process of claim 27, wherein at least one of R¹, R² and R³ are independently provided with a protective group.

30. (Original) The process of claim 27, further comprising the step of saponifying any ester groups existing when the reacting step has ended or bringing the product formed when the reacting step has ended into contact with a strong base, which strong base may already contain the desired cation, in order to form a salt.

31. (Original) The process of claim 27, wherein the duration of the reaction is 0.25 - 12 hours.


32. (Original) The process of claim 27, wherein the duration of the reaction is no longer than 2 hours.

33. (Original) The process of claim 27, wherein the reaction is carried out at a temperature of between 20°C and 40°C.

34. (Original) The process of claim 27, wherein the reaction is carried out at room temperature.

35. (Original) The process of claim 27, wherein the reaction is a single-vessel reaction.


36. (Previously Presented) A process for preparing a substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compound corresponding to formula I of claim 1, wherein $R^4 \neq H$,



I,


comprising the steps of:

reacting an aniline corresponding to formula II, a glyoxalic acid ester or a glyoxalic acid corresponding to formula III and an olefin of formula IV, with trifluoroacetic acid to form a reaction product wherein $R^4 = H$




II

+



III

+



IV

reacting said reaction product to substitute the H on R⁴ with

R^{4a} or ZR^{4a}, where Z = C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; and R^{4a} represents

C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl or C₂-C₁₂-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

C(O)R⁹, C(O)OR⁹, C(S)R⁹, C(S)OR⁹ or S(O₂)R⁹, where R⁹ represents

H; C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted, especially phenethyl, 1-adamantyl, 2-adamantyl, 1-naphthyl or 2-naphthyl, 2-, 3- or 4-pyridyl or thiazolyl;

SR¹⁰, where R¹⁰ represents

aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted;

C(O)NR¹¹R¹², C(O)NR¹¹NR¹²R¹³, C(NR¹¹)NR¹²R¹³, C(S)NR¹¹R¹² or C(S)NR¹¹NR¹²R¹³, where R¹¹, R¹² and R¹³ independently represent

H; C₁-C₁₈-alkyl, C₂-C₁₈-alkenyl or C₂-C₁₈-alkynyl, each of which is branched or unbranched and monosubstituted or polysubstituted or unsubstituted; C₃-C₈-cycloalkyl which is saturated or unsaturated and monosubstituted or polysubstituted or unsubstituted, or a corresponding heterocycle in which at least one ring C atom is replaced by S, O or N; alkylaryl or alkylheteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted; and aryl or heteroaryl, each of which is monosubstituted or polysubstituted or unsubstituted.

37. (previously presented) The process of claim 27, wherein in at least one of the aniline corresponding to formula II, the glyoxalic acid ester or glyoxalic acid compound corresponding to formula III or the benzofuran corresponding to formula IV, are independently provided with a protective group, said protective group being selected from the group consisting of

OSi(Ph)₂tert-butyl to replace an OH group;

S-p-methoxybenzyl to replace an SH group and

NO₂ to replace an NH₂ group and

before a purification step,

at least one OSi(Ph)₂tert-butyl group is cleaved with tetrabutylammonium fluoride in tetrahydrofuran;

at least one p-methoxybenzyl group is cleaved with a metal amide or

at least one NO₂ group is reduced to NH₂.

38. (original) The process of claim 37, wherein said metal amide is sodium amide.

39. (original) The process of claim 37, wherein, before a purification step,

all OSi(Ph)₂tert-butyl groups are cleaved with tetrabutylammonium fluoride in tetrahydrofuran;

all p-methoxybenzyl groups are cleaved with a metal amide or
all NO₂ groups are reduced to NH₂.

40. (previously presented) The process of claim 27, wherein a product of the process with at least one C(O)OCH₃ or C(S)OCH₃ group, or a product of the process wherein R³ = C₁₋₄-alkyl, is saponified with KOH solution or NaOH solution in methanol or ethanol at a temperature of from 0°C - 100°C.

41. (original) The process of claim 40, wherein said temperature is from 40°C - 60°C.

42. (original) The process of claim 40, wherein in said product of the process, R³ = CH₃ or C₂H₅.

43. (original) A pharmaceutical composition, comprising:

at least one salt of a substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compound corresponding to formula I of claim 1 and
an auxiliary agent.

44. (original) The pharmaceutical composition of claim 43, wherein said compound is present in the form of a pure enantiomer or pure diastereoisomer.

45. (original) The pharmaceutical composition of claim 43, wherein said compound is present in the form of a mixture of stereoisomers.

46. (original) The pharmaceutical composition of claim 43, wherein said compound is present in the form of a racemic mixture.

47. (currently amended) A method of ~~alleviating~~ treating pain in a mammal, said method comprising administering to said mammal an effective pain ~~alleviating~~ treating amount of a compound according to claim 1.

48. (original) The method of claim 47, wherein said pain is neuropathic or chronic pain.

49. (original) The method of claim 47, wherein said pain is pain from a migraine.

50. (canceled)

51. (currently amended) A method of treating ~~or inhibiting~~ epilepsy, ~~Parkinson's disease, Huntington's chorea, glaucoma, the withdrawal symptoms associated with alcohol or drug abuse,~~ stroke, and cerebral ischaemia, ~~hypoxia, anoxia or for anxiolysis or anaesthesia in a mammal,~~ said method comprising administering to said mammal an effective amount of a compound according to claim 1.

52. (canceled)